704 related articles for article (PubMed ID: 27533321)
1. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
2. [Dermatomyositis and Autoantibodies].
Fujimoto M
Brain Nerve; 2018 Apr; 70(4):427-438. PubMed ID: 29632290
[TBL] [Abstract][Full Text] [Related]
3. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
[TBL] [Abstract][Full Text] [Related]
4. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
5. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
6. [Dermatomyositis: new antibody, new classification].
Bolko L; Gitiaux C; Allenbach Y
Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626
[TBL] [Abstract][Full Text] [Related]
7. [Dermatomyositis associated with anti-MDA5 autoantibody].
Collado MV; Gargiulo MLÁ; Gómez R; Gómez G; Pérez N; Suarez L; Taratuto AL; Aruj P
Medicina (B Aires); 2018; 78(5):360-363. PubMed ID: 30285929
[TBL] [Abstract][Full Text] [Related]
8. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
9. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
10. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
11. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
12. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease.
Gono T; Tanino Y; Nishikawa A; Kawamata T; Hirai K; Okazaki Y; Shibata Y; Kuwana M
Int J Rheum Dis; 2019 Aug; 22(8):1582-1586. PubMed ID: 31050194
[TBL] [Abstract][Full Text] [Related]
13. Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.
Wolstencroft PW; Fiorentino DF
Curr Rheumatol Rep; 2018 Apr; 20(5):28. PubMed ID: 29637414
[TBL] [Abstract][Full Text] [Related]
14. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977
[TBL] [Abstract][Full Text] [Related]
15. The clinical spectrum of dermatomyositis and the new autoantibodies - with regard to two clinical cases with distinct associations.
Calvão da Silva JCM; Santiago L; Brites MM; Gonçalo M
Australas J Dermatol; 2020 May; 61(2):e241-e243. PubMed ID: 31881093
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients].
Bodoki L; Budai D; Nagy-Vincze M; Griger Z; Betteridge Z; Dankó K
Orv Hetil; 2015 Sep; 156(36):1451-9. PubMed ID: 26320599
[TBL] [Abstract][Full Text] [Related]
18. Dermatomyositis: Clinical features and pathogenesis.
DeWane ME; Waldman R; Lu J
J Am Acad Dermatol; 2020 Feb; 82(2):267-281. PubMed ID: 31279808
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
20. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
Ueki M; Kobayashi I; Takezaki S; Tozawa Y; Okura Y; Yamada M; Kuwana M; Ariga T
Mod Rheumatol; 2019 Mar; 29(2):351-356. PubMed ID: 29532710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]